Pemetrexed + Erlotinib + Pemetrexed + Erlotinib
Phase 2CompletedDevelopment Stage
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
Mar 1, 2007 → Jun 1, 2011
About Pemetrexed + Erlotinib + Pemetrexed + Erlotinib
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib is a phase 2 stage product being developed by Eli Lilly for Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.. The current trial status is completed. This product is registered under clinical trial identifier NCT00447057. Target conditions include Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy..
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00447057 | Phase 2 | Completed |
Competing Products
3 competing products in Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Gefitinib, 5-fluorouracil, leucovorin and radiotherapy | AstraZeneca | Phase 1/2 | 24 |
| ASA404 | Novartis | Phase 1 | 21 |
| AMG 706 | Amgen | Phase 1 | 29 |